- Home
- ANGO vs BNTC Comparison
ANGO vs BNTC Comparison
Compare ANGO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- BNTC
- Stock Information
- Founded
- ANGO 1988
- BNTC 1995
- Country
- ANGO United States
- BNTC United States
- Employees
- ANGO N/A
- BNTC N/A
- Industry
- ANGO Medical/Dental Instruments
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- BNTC Health Care
- Exchange
- ANGO Nasdaq
- BNTC Nasdaq
- Market Cap
- ANGO 401.4M
- BNTC 339.8M
- IPO Year
- ANGO 2004
- BNTC N/A
- Fundamental
- Price
- ANGO $9.39
- BNTC $12.88
- Analyst Decision
- ANGO Strong Buy
- BNTC Strong Buy
- Analyst Count
- ANGO 3
- BNTC 7
- Target Price
- ANGO $13.00
- BNTC $24.43
- AVG Volume (30 Days)
- ANGO 479.1K
- BNTC 57.1K
- Earning Date
- ANGO 04-02-2025
- BNTC 05-12-2025
- Dividend Yield
- ANGO N/A
- BNTC N/A
- EPS Growth
- ANGO N/A
- BNTC N/A
- EPS
- ANGO N/A
- BNTC N/A
- Revenue
- ANGO $286,498,000.00
- BNTC N/A
- Revenue This Year
- ANGO N/A
- BNTC N/A
- Revenue Next Year
- ANGO $6.63
- BNTC N/A
- P/E Ratio
- ANGO N/A
- BNTC N/A
- Revenue Growth
- ANGO N/A
- BNTC N/A
- 52 Week Low
- ANGO $5.47
- BNTC $4.75
- 52 Week High
- ANGO $13.50
- BNTC $16.90
- Technical
- Relative Strength Index (RSI)
- ANGO 43.99
- BNTC 45.06
- Support Level
- ANGO $9.34
- BNTC $11.86
- Resistance Level
- ANGO $10.29
- BNTC $15.08
- Average True Range (ATR)
- ANGO 0.39
- BNTC 1.13
- MACD
- ANGO 0.06
- BNTC -0.36
- Stochastic Oscillator
- ANGO 32.84
- BNTC 20.24
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.